Seres Therapeutics Inc expected to post a loss of 50 cents a share - Earnings Preview

Seres Therapeutics

01/03/2024 14:11

* Seres Therapeutics Inc  MCRB.OQ   MCRB.O  is expected
to show a
fall in quarterly revenue when it reports  results on March 5
for the period ending December 31 2023
    * The Cambridge Massachusetts-based  company is expected to
report
a 65.2% decrease in revenue to $350 thousand from $1.01 million
a year ago, according to the mean estimate from 6 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Seres Therapeutics Inc
is for
a loss of 50 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Seres
Therapeutics Inc is $10.00​, above​ its last closing price
of $1.14. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.49       -0.50      -0.37     Beat    26.2
 Jun. 30 2023  0.53        0.53       0.36      Missed  -32.6
 Mar. 31 2023  -0.56       -0.55      -0.57     Missed  -3.8​
 Dec. 31 2022  -0.30       -0.46      -0.54     Missed  -16.1
 ​​Sep.        -0.50       -0.47      -0.49     Missed  -4.5
 30 2022                                                
 Jun. 30 2022  -0.59       -0.60      -0.70     Missed  -17.4​
 Mar. 31 2022  -0.54       -0.52      -0.61     Missed  -16.4
 Dec. 31 2021  -0.44       -0.44      -0.52     Missed  -19.1
 This summary was machine generated March 1 at 14:11 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)